Keyphrases
Clinical Trials
100%
C-C Chemokine Receptor Type 5 (CCR5)
100%
Maraviroc
100%
Post-stroke Depression
100%
Therapeutic Potential
50%
Montgomery-asberg Depression Rating Scale
50%
Treatment-related Adverse Events
33%
Treatment Cessation
16%
Mechanism-based
16%
Oral Dose
16%
Primary Outcome Measure
16%
Daily Dose
16%
Serious Adverse Events
16%
Remission
16%
Current Therapeutics
16%
Possible Mechanisms
16%
Placebo-controlled Study
16%
Intolerance
16%
Trial Registration
16%
Pharmacological Approaches
16%
Efficient Recovery
16%
Proof of Concept Study
16%
Treatment Phase
16%
Time Response
16%
Successful Rehabilitation
16%
No-report
16%
CCR5 Antagonist
16%
Unmet Demand
16%
Cortical Stroke
16%
Subcortical Stroke
16%
Medicine and Dentistry
Clinical Trial
100%
Post-Stroke Depression
100%
Maraviroc
100%
Adverse Event
50%
Montgomery-Åsberg Depression Rating Scale
50%
Apoplexy
33%
Placebo-Controlled Study
16%
Chemokine Receptor CCR5 Antagonist
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Maraviroc
100%
Post-Stroke Depression
100%
Adverse Event
50%
Cerebrovascular Accident
33%
Remission
16%
Placebo-Controlled Study
16%
Chemokine Receptor CCR5 Antagonist
16%